A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005) - Trial NCT06305767
Access comprehensive clinical trial information for NCT06305767 through Pure Global AI's free database. This Phase 2 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Bladder Cancer. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 2
Mar 28, 2024
Apr 08, 2031
Primary Outcome
Disease Free Survival (DFS)
Summary
The purpose of this study is to assess the safety and efficacy of V940 in combination with
 pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for
 participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after
 radical resection. The primary study hypothesis is that V940 in combination with
 pembrolizumab results in a superior disease-free survival (DFS) as assessed by the
 investigator compared to pembrolizumab alone in participants with high-risk MIUC after
 radical resection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06305767
Non-Device Trial